stockportfolio.pro
CorMedix Inc. (CRMD)
Healthcare · Biotechnology · NasdaqGM
CorMedix Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $224,105 | $329,327 | $429,797 | $283,266 | $239,231 | $190,936 | $65,408 | $0 | $43.47M | $311.71M |
| Gross profit | $-142,568 | $214,363 | $33,011 | $-89,968 | $34,385 | $41,998 | $61,674 | — | $40.28M | $275.75M |
| Net income | $-24.64M | $-33.01M | $-26.83M | $-16.43M | $-22.03M | $-28.21M | $-29.70M | $-46.34M | $-17.93M | $163.06M |
| Net margin | -10996.5% | -10023.4% | -6242.4% | -5801.3% | -9207.7% | -14774.7% | -45409.9% | — | -41.2% | 52.3% |
Source: CorMedix Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into CRMD stock?
At today's market cap of $697.44M, CorMedix Inc. is priced for free-cash-flow growth of about -15.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $172.79M from the FY ending 2025-12-31). For comparison, revenue 319.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of CorMedix Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CRMD in your portfolio →
CorMedix Inc. financial history by metric
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
CorMedix Inc. — frequently asked questions
What is CorMedix Inc.'s revenue?
CorMedix Inc. (CRMD) reported revenue of $311.71M for fiscal year 2025, up 617.0% from the prior year, according to its SEC filings.
Is CorMedix Inc. profitable?
Yes. CRMD earned net income of $163.06M in fiscal 2025, a net margin of 52.3%.
What is CRMD's P/E ratio?
CorMedix Inc. trades at a price-to-earnings ratio of about 4.1 based on the latest data in our nightly-refreshed cache.
How fast is CorMedix Inc. growing?
CRMD's revenue grew at roughly 319.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does CorMedix Inc. have?
As of fiscal year 2025, CRMD carried roughly $144.63M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is CorMedix Inc.'s gross margin?
CRMD's gross margin was 88.5% in fiscal 2025 — gross profit of $275.75M on revenue of $311.71M.
What is CorMedix Inc.'s market cap?
CorMedix Inc. (CRMD) has a market capitalization of about $697.44M, based on the latest data in our nightly-refreshed cache.
When does CorMedix Inc.'s fiscal year end?
CRMD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CRMD stock?
At today's market cap of $697.44M, CorMedix Inc. is priced for free-cash-flow growth of about -15.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $172.79M from the FY ending 2025-12-31). For comparison, revenue 319.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from CorMedix Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.